SCHEDULE: Viking Global Reduces Roivant Sciences Stake to 3.4%

Sentiment:

Beneficial Ownership Report 14 November 2025 4:54 PM

Viking Global Investors LP and its affiliates have reduced their beneficial ownership in Roivant Sciences Ltd. to 3.4% of common shares.

Worse than expectedViking Global Investors LP and its affiliates have reduced their beneficial ownership in Roivant Sciences Ltd. to 3.4% of common shares outstanding, down from a previously held stake that was above the 5% threshold (implied by the filing of an amendment to Schedule 13G showing ownership below 5%). This reduction by a major institutional investor can be perceived negatively by the market.

Summary

Viking Global Investors LP and its affiliated entities, including Viking Global Performance LLC, Viking Global Equities Master Ltd., and Viking Global Opportunities Illiquid Investments Sub-Master LP, along with individuals O. Andreas Halvorsen, David C. Ott, and Rose S. Shabet, collectively beneficially own 23,594,831 common shares of Roivant Sciences Ltd.
This aggregate ownership represents 3.4% of Roivant Sciences Ltd.'s common shares outstanding.
The percentage is based on 689,697,370 common shares outstanding as of September 30, 2025, as reported by Roivant Sciences Ltd. in its Form 10-Q.
The filing is an Amendment No. 6 to Schedule 13G, indicating a change from a previously reported beneficial ownership position.

Sentiment

Score: 4

Explanation: The sentiment is slightly negative due to a significant institutional investor reducing its stake below the 5% threshold, which can be interpreted as a loss of conviction or a strategic divestment.

Negatives

A significant institutional investor, Viking Global Investors LP and its affiliates, has reduced its stake in Roivant Sciences Ltd. to below the 5% threshold, which could be interpreted as a decrease in conviction or a reallocation of capital.

Future Outlook

Industry Context

The reduction in stake by a prominent investment firm like Viking Global Investors could be a signal for other investors in the biotechnology and pharmaceutical sectors, potentially influencing sentiment towards Roivant Sciences Ltd. or similar companies.

Stakeholder Impact

Shareholders may react negatively to the news of a major institutional investor reducing its stake, potentially leading to downward pressure on the stock price.
Potential investors might view this reduction as a cautionary signal, influencing their investment decisions regarding Roivant Sciences Ltd.

Key Dates

Date	Description
09/30/2025	Date of event which requires filing of this statement, and the date for which shares outstanding were reported by the Issuer.
11/10/2025	Date Roivant Sciences Ltd. filed its quarterly report on Form 10-Q, reporting 689,697,370 common shares outstanding.
11/14/2025	Date of the Schedule 13G Amendment No. 6 filing.

Recommendation

hold

While a major institutional investor has reduced its stake, this filing alone does not provide enough fundamental information about Roivant Sciences Ltd.'s operational performance or future prospects to warrant a strong buy or sell recommendation. The reduction in stake by Viking Global Investors LP suggests a potential re-evaluation of the investment thesis, but without further context on the reasons for the divestment or the company's current financial health, a 'hold' recommendation is prudent for seasoned investors to await more comprehensive data.

Keywords

Roivant Sciences, Viking Global Investors, Beneficial Ownership, Institutional Investor, SEC Filing, Schedule 13G, Common Shares, Biotechnology, Pharmaceuticals

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.